Xi'an Dome Medical Technology

The founding team has a strong background in neuromodulation, with their research into the field dating back to 2015. The co-founder and CEO, Dr. Li Long, graduated from Xi'an Jiaotong University, specializing in nervous system functional intervention technology. The co-founder and Chief Scientist, Wang Jue, is a recognized expert in the Chinese neuromodulation field. This expertise has enabled the company to develop a significant technical barrier in the TI stimulation field. In May 2025, the company appointed Nir Grossman, the inventor of TI technology, as its exclusive chief technical advisor.

Neurodome's business model revolves around the development and application of its TI technology for both clinical and research purposes. The company's technology works by applying two high-frequency currents to the surface of the brain, which interfere with each other internally to create a low-frequency field that can selectively stimulate deep brain regions without affecting the cortex. This approach overcomes the limitations of traditional methods like Deep Brain Stimulation (DBS), which require invasive surgery. The company targets a large market, with nearly 130 million people in China suffering from various brain diseases such as depression, Alzheimer's, and Parkinson's. Its client base includes over a hundred hospitals and scientific research institutions across departments like neurology, neurosurgery, psychiatry, and rehabilitation.

The company has developed several product lines, including the NervioX-1000 for research and the TIs-EMO-1000 for medical use, alongside MRI-compatible kits, feedback systems, navigation software, and animal electrodes. These products are designed for a wide range of applications, including the treatment of epilepsy, Parkinson's disease, stroke, sleep disorders, depression, anxiety, and addiction. Neurodome has undergone multiple financing rounds to support its growth, including an angel round from Peak Rock Capital and Shunwei Capital, a Pre-A round of tens of millions of yuan in December 2023, and a recent A+ round of nearly 100 million yuan in March 2026.